INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 186 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $90,687,000 | +218.6% | 717,696 | +111.6% | 0.60% | +90.1% |
| Q2 2018 | $28,465,000 | +36.4% | 339,232 | 0.0% | 0.31% | +65.6% |
| Q1 2018 | $20,870,000 | +5.3% | 339,232 | 0.0% | 0.19% | +14.5% |
| Q4 2017 | $19,818,000 | +0.7% | 339,232 | 0.0% | 0.16% | -2.9% |
| Q3 2017 | $19,689,000 | -58.2% | 339,232 | -12.8% | 0.17% | -51.3% |
| Q2 2017 | $47,124,000 | +14.4% | 389,232 | +6.9% | 0.35% | -8.6% |
| Q1 2017 | $41,195,000 | -18.3% | 364,232 | -21.5% | 0.38% | -8.6% |
| Q4 2016 | $50,439,000 | +9.7% | 464,232 | +66.3% | 0.42% | -3.0% |
| Q3 2016 | $45,959,000 | -36.6% | 279,232 | -45.1% | 0.43% | -31.8% |
| Q2 2016 | $72,515,000 | +134.8% | 508,232 | +111.4% | 0.63% | +119.4% |
| Q1 2016 | $30,883,000 | +8.7% | 240,392 | +26.4% | 0.29% | +17.6% |
| Q4 2015 | $28,410,000 | +82.4% | 190,226 | +102.5% | 0.24% | +78.8% |
| Q3 2015 | $15,579,000 | +232.2% | 93,926 | +383.5% | 0.14% | +226.2% |
| Q2 2015 | $4,689,000 | -14.4% | 19,426 | 0.0% | 0.04% | -14.3% |
| Q1 2015 | $5,479,000 | – | 19,426 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |